Lotus Pharmaceuticals, Inc.
LTUS
$0.0053
-$0.0007-11.67%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | 4.04% | -1.12% | -12.43% | 21.95% | 26.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.04% | -1.12% | -12.43% | 21.95% | 26.13% |
| Cost of Revenue | 98.48% | 51.63% | 8.34% | 18.60% | 32.24% |
| Gross Profit | -68.07% | -50.14% | -27.67% | 25.19% | 21.83% |
| SG&A Expenses | -56.22% | -30.24% | -0.47% | 94.13% | 43.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.97% | 34.64% | 13.07% | 44.89% | 35.83% |
| Operating Income | -81.24% | -71.84% | -57.68% | -45.83% | 12.41% |
| Income Before Tax | -81.84% | -72.67% | -55.57% | -230.24% | 26.25% |
| Income Tax Expenses | -- | -- | -99.90% | -218.13% | 167.78% |
| Earnings from Continuing Operations | -81.29% | -71.94% | -54.65% | -231.19% | 24.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.29% | -71.94% | -54.65% | -231.19% | 24.28% |
| EBIT | -81.24% | -71.84% | -57.68% | -45.83% | 12.41% |
| EBITDA | -76.71% | -67.64% | -53.87% | -37.55% | 13.15% |
| EPS Basic | -82.07% | -73.25% | -59.33% | -213.60% | 2.41% |
| Normalized Basic EPS | -82.54% | -73.87% | -59.97% | -43.99% | 3.99% |
| EPS Diluted | -82.16% | -73.17% | -55.33% | -226.68% | 13.64% |
| Normalized Diluted EPS | -82.50% | -73.77% | -57.05% | -36.28% | 16.10% |
| Average Basic Shares Outstanding | 4.07% | 4.69% | 10.94% | 15.49% | 21.36% |
| Average Diluted Shares Outstanding | 3.87% | 4.17% | 3.52% | 1.51% | 8.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |